A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Clinical Trial ID NCT00948961

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.	Oncoimmunology	2012	1.88
2	Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.	Sci Transl Med	2014	1.30
3	Immunological landscape and immunotherapy of hepatocellular carcinoma.	Nat Rev Gastroenterol Hepatol	2015	1.06
4	Immunotherapy in ovarian cancer.	Hum Vaccin Immunother	2012	0.99
5	Harnessing Human Cross-Presenting CLEC9A(+)XCR1(+) Dendritic Cells for Immunotherapy.	Front Immunol	2014	0.88
6	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.	Oncoimmunology	2015	0.85
7	Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.	Front Pharmacol	2013	0.82
8	Current Immunotherapies for Sarcoma: Clinical Trials and Rationale.	Sarcoma	2016	0.79
9	Recent advances and future of immunotherapy for glioblastoma.	Expert Opin Biol Ther	2016	0.77
10	The Role of Immunotherapy in Multiple Myeloma.	Pharmaceuticals (Basel)	2016	0.77
11	Personalized therapy for urothelial cancer: review of the clinical evidence.	Clin Investig (Lond)	2011	0.76
12	NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.	Oncotarget	2014	0.76
13	Cancer testis antigen and immunotherapy.	Immunotargets Ther	2013	0.76